MedTrace Logo

A Study in Patients With Major Depressive Disorder

NCT03642964 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-07-11

No results posted yet for this study

Summary

This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

CTC-501

pramipexole IR, given with ondansetron

Sponsors & Collaborators

  • Chase Therapeutics Corporation

    lead INDUSTRY

Principal Investigators

  • Mark Leibowitz, MD · Collaborative Neuroscience Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2025-12-30
Completion
2025-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642964 on ClinicalTrials.gov